Nuveen
KYNB

Nuveen’s Kyntra Bio KYNB Stock Holding History

Nuveen’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,324
Closed -$195K – 3365
2024
Q1 		$195K Hold
3,324
– – ﹤0.01% 3191
2023
Q4 		$73.6K Hold
3,324
– – ﹤0.01% 3296
2023
Q3 		$71.7K Hold
3,324
– – ﹤0.01% 3145
2023
Q2 		$224K Sell
3,324
-32,528
-91% -$13.5M ﹤0.01% 3074
2023
Q1 		$16.7M Buy
35,852
+13,159
+58% +$6.96M 0.01% 1165
2022
Q4 		$9.09M Sell
22,693
-1,036
-4% -$397K ﹤0.01% 1553
2022
Q3 		$7.72M Buy
23,729
+13,136
+124% +$4.23M ﹤0.01% 1642
2022
Q2 		$2.8M Buy
10,593
+89
+0.8% +$22.7K ﹤0.01% 2263
2022
Q1 		$3.39M Sell
10,504
-3,253
-24% -$1.13M ﹤0.01% 2266
2021
Q4 		$4.85M Sell
13,757
-192
-1% -$59.8K ﹤0.01% 2142
2021
Q3 		$3.56M Sell
13,949
-2,742
-16% -$972K ﹤0.01% 2390
2021
Q2 		$11.1M Buy
16,691
+1,455
+10% +$838K ﹤0.01% 1804
2021
Q1 		$13.2M Sell
15,236
-1,475
-9% -$1.57M ﹤0.01% 1618
2020
Q4 		$15.5M Sell
16,711
-1,767
-10% -$1.86M 0.01% 1413
2020
Q3 		$19M Buy
18,478
+9
+0% +$9.68K 0.01% 1092
2020
Q2 		$18.7M Sell
18,469
-2,204
-11% -$2.05M 0.01% 1089
2020
Q1 		$18M Sell
20,673
-9,313
-31% -$9.26M 0.01% 961
2019
Q4 		$32.2M Buy
29,986
+9,506
+46% +$9.7M 0.01% 905
2019
Q3 		$18.9M Buy
20,480
+3,748
+22% +$4.12M 0.01% 1165
2019
Q2 		$18.9M Buy
16,732
+16,220
+3,168% +$17.8M 0.01% 1185
2019
Q1 		$696K Buy
+512
New +$694K ﹤0.01% 794
2018
Q4 		– Sell
-912
Closed -$1.39M – 1021
2018
Q3 		$1.39M Sell
912
-52
-5% -$80.1K 0.01% 707
2018
Q2 		$1.51M Buy
964
+144
+18% +$188K 0.01% 660
2018
Q1 		$948K Sell
820
-2
-0.2% -$2.63K 0.01% 759
2017
Q4 		$974K Sell
822
-3
-0.4% -$3.76K 0.01% 753
2017
Q3 		$1.11M Buy
+825
New +$869K 0.01% 738

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nuveen's KYNB Position: Q2 2024 in Review

Nuveen sold out of Kyntra Bio (KYNB) in Q2 2024, closing a stake of 3,324 shares — an estimated $195K sold.

Nuveen first reported a position in KYNB in Q3 2017 and held it in 26 quarters. The position peaked at $32.2M in Q4 2019. 102 funds tracked by Wall St. Rank hold KYNB as of Q2 2024.

  • Nuveen reported no remaining Kyntra Bio position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 3,324 Kyntra Bio shares in Q2 2024, an estimated $195K.
  • Nuveen first reported a position in Kyntra Bio in Q3 2017 and held it in 26 quarters.
  • Nuveen's Kyntra Bio position peaked at $32.2M in Q4 2019.
  • 102 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.